Johnson & Johnson (JNJ) Common Equity (2009 - 2026)

Johnson & Johnson has disclosed Common Equity across 18 years of filings, most recently posting $81.2 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $81.2 billion, up 3.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.2 billion (up 3.94% YoY), and the FY2025 annual result was $81.5 billion, up 14.06% from the prior year.
• Common Equity came in at $81.2 billion for Q1 2026 at Johnson & Johnson, roughly flat from $81.5 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $81.5 billion in Q4 2025 to a low of $68.8 billion in Q4 2023.
• The 5-year median for Common Equity is $74.7 billion (2022), against an average of $74.8 billion.
• Across the five-year window, Common Equity climbed 16.98% in 2022 and decreased 10.46% in 2023, its largest moves.
• Johnson & Johnson's Common Equity stood at $74.6 billion in 2022, then fell by 7.81% to $68.8 billion in 2023, then advanced by 3.95% to $71.5 billion in 2024, then advanced by 14.06% to $81.5 billion in 2025, then retreated by 0.44% to $81.2 billion in 2026.
• The last three Common Equity figures came in at $81.2 billion (Q1 2026), $81.5 billion (Q4 2025), and $79.3 billion (Q3 2025), per Business Quant data.